A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.

@article{Ong2016ANC,
  title={A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.},
  author={Pei-Shi Ong and Ling Wang and Deborah Miao-Hui Chia and Jolyn Yu-Xin Seah and Li-Ren Kong and Win-Lwin Thuya and Arunachalam Chinnathambi and J A Lau and Andrea Li-Ann Wong and W Yong and Daiwen Yang and Paul C Ho and Gautam Sethi and Boon-cher Goh},
  journal={Cancer letters},
  year={2016},
  volume={381 1},
  pages={49-57}
}
With conventional anticancer agents for non-small cell lung cancer (NSCLC) reaching therapeutic ceiling, the novel combination using histone deacetylase inhibitor, PXD101 (Belinostat(®)), and CDK inhibitor, CYC202 (Seliciclib(®)), was investigated as an alternative anticancer strategy. At clinically achievable concentration of CYC202 (15 µM), combination therapy resulted in significant reduction in cell proliferation (IC50 = 3.67 ± 0.80 µM, p < 0.05) compared with PXD101 alone (IC50 = 6.56 ± 0… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
0 Extracted Citations
53 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 53 references

W

  • L. Z. Wang, J. Ramírez
  • Yeo, M.Y. Chan, W.L. Thuya, J.Y. Lau, et al…
  • 2013
1 Excerpt

Y

  • T. Qiu, L. Zhou, W. Zhu, T. Wang, J. Wang
  • Shu, et al., Effects of treatment with histone…
  • 2013
2 Excerpts

E

  • G. L. Gravina, F. Marampon, I. Giusti, E. Carosa, S. Di Sante
  • Ricevuto, et al., Differential effects of PXD101…
  • 2012
1 Excerpt

J

  • W. Yeo, H. C. Chung, S. L. Chan, L. Z. Wang, R. Lim
  • Picus, et al., Epigenetic therapy using…
  • 2012

Similar Papers

Loading similar papers…